Massachusetts Lawmakers Prioritize Health Policy
Katherine O'Malley
August 12, 2026
Massachusetts lawmakers made health policy their central focus of the 2025-2026 legislative session.
Massachusetts lawmakers made health policy their central focus of the 2025-2026 legislative session.
Massachusetts lawmakers made health policy their central focus of the 2025-2026 legislative session.
Yesterday, I highlighted a Commonwealth Study comparing twelve industrialized nations to show how we’re paying more for the same drugs. Today, I want to point
By tweet, I was asked where to find estimates of the cost of a single payer health system. I turned to Aaron and Don who
In case there is any doubt, a new study using experimental methods shows that how physicians get paid and by how much does affect patient
John Goodman and Thomas Saving have published a post at Health Affairs that aims to dismantle the notion that Medicare spending grows more slowly than
The number one cause of death in children is accidents. More kids die of unintentional injuries than any disease. In kids age 10-14, the number
Aaron is correct that US drug prices are higher than other OECD countries. The US is less willing to use government monopsony reimbursement rules to
Sound Medicine is a radio show produced by the Indiana University School of Medicine and WFYI Public Radio. I was a guest earlier this week, talking about our Vermont’s
This is a FAQ entry. See the main FAQ index for others. See also the related entry on premium support. Here’s a list of some posts on competitive
Implied private rights of action have suffered a long string of defeats under the Rehnquist and Roberts Courts. In October, SCOTUS will hear another one,
Every time I offer a way to reduce health car spending that doesn’t involve cost-shifting, someone argues that if we spend less, the quality of
How good a program is the Medicare Part D drug benefit (implemented in 2006)? Your answer should depend on what you compare it to and
Tyler gives high marks to Ezekiel Emanuel’s Opinion in the NYT on reimbursement problems for generic Part B cancer drugs,* leading to shortages. Emanuel describes